Workshop 'Immuno-imaging and Molecular Therapy'
Published on 21.03.2018
Please find below the message of the team of the In Vivo Cellular and Molecular Imaging (ICMI) Lab of the Free University Brussels (VUB): www.icmibrussels.be
"Dear researcher, Dear student,
We would like to announce the annual workshop 'Immuno-imaging and Molecular Therapy' which will be held from April 23-27 in Brussels, Belgium.
This 5-day workshop, organised by the ICMI lab in Brussels, aims to offers lectures by national and international experts in the fields of antibody-engineering, clinical and preclinical nuclear imaging, tracer design, image acquisition and reconstruction, (radio) chemistry, targeted radionuclide therapy, optical imaging, immunogenicity and intellectual property. Altogether, a full overview of the research topic ‘Immunotheranostics’ will be provided through the organization of 13 lectures and 2 half-day hands-on sessions. A special focus will be put on nanobodies as an example of engineered antibody vehicles for non-invasive imaging and targeted therapy.
The full program and more details can be found in the attached document.
This is already the fifth edition of the workshop. Previous editions of the workshop took place in the spring of 2014-2017, with a similar outline and scope.
We particularly welcome (inter)national master and PhD students interested in this topic as well as postdoctoral scientists. The registration fee is €250 for the full 5-day program. This includes workshop attendance, lunches, refreshments and participation to the social event. Please register by filling in the attached form and sending it to email@example.com. The registration process is completed upon receipt of the completed registration form and a proof-of-payment.
Remark: in contrast to the lectures, there is a limitation to the number of participants to the hands-on sessions. Registration to the practical training session will be handled on a first-come/first-serve basis.
Please feel free to pass on this announcement to anyone who might be interested.
The ICMI team,